Jazz Pharmaceuticals PLC $JAZZ Shares Bought by EP Wealth Advisors LLC

by · The Markets Daily

EP Wealth Advisors LLC raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 87.4% during the first quarter, HoldingsChannel reports. The firm owned 3,303 shares of the specialty pharmaceutical company’s stock after buying an additional 1,540 shares during the period. EP Wealth Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $410,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Hurley Capital LLC acquired a new position in Jazz Pharmaceuticals in the first quarter valued at $25,000. Elequin Capital LP increased its stake in Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares during the period. Parallel Advisors LLC increased its stake in Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 119 shares during the period. Picton Mahoney Asset Management increased its stake in Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 269 shares during the period. Finally, Spire Wealth Management boosted its holdings in shares of Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 161 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Up 1.2%

Shares of NASDAQ JAZZ opened at $129.50 on Monday. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The firm has a 50-day moving average price of $116.68 and a 200 day moving average price of $116.77. The stock has a market capitalization of $7.86 billion, a price-to-earnings ratio of -19.24, a price-to-earnings-growth ratio of 8.03 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same quarter last year, the business earned $5.30 EPS. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the sale, the director owned 429,973 shares in the company, valued at $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Truist Financial lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Royal Bank Of Canada lifted their target price on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a report on Thursday, August 28th. Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Wall Street Zen downgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 15th. Finally, Morgan Stanley lifted their target price on shares of Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an “overweight” rating in a report on Thursday, August 28th. Fourteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $178.67.

Read Our Latest Research Report on JAZZ

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

See Also

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).